血清Cripto-1在非小细胞肺癌患者中的诊断和预后价值。

Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.

作者信息

Xu Chun Hua, Chi Chuan Zhen, Zhang Qian, Wang Yu Chao, Wang Wei, Yuan Qi, Zhan Ping, Zhang Xiu Wei, Lin Yong

机构信息

Endoscopic Center of Nanjing Chest Hospital, Nanjing, Jiangsu 210029, People's Republic of China.

Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu 210029, People's Republic of China.

出版信息

Clin Respir J. 2018 Oct;12(10):2469-2474. doi: 10.1111/crj.12793. Epub 2018 Sep 23.

DOI:10.1111/crj.12793

PMID:29570945

Abstract

INTRODUCTION

Cripto-1 (CR-1) is a member of the epidermal growth factor (EGF)-CFC protein family, which is involved in tumor pathogenesis.

OBJECTIVES

This study aimed to explore the diagnostic and prognostic value of serum CR-1 level in patients with non-small cell lung cancer (NSCLC).

METHODS

Serum specimens from 312 NSCLC patients and 120 healthy controls were collected. Serum CR-1 level was measured using enzyme-linked immunosorbent assay.

RESULTS

The serum CR-1 level was significantly elevated in NSCLC patients compared with healthy controls (P < .001). Higher serum CR-1 level was associated with advanced TNM stage, lymph node metastasis and distant metastasis. With a cutoff value of 1.67 ng/mL, CR-1 showed a good diagnostic performance for NSCLC. Kaplan-Meier log rank analysis revealed that the low serum CR-1 patients had a better overall survival (OS) and progression-free survival (PFS) compared with high CR-1 patients (P = .004 and .001, respectively). Further univariate and multivariate Cox regression analyses showed that serum CR-1 level was an independent risk factor of prognosis of NSCLC patients.

CONCLUSIONS

Our study suggests that serum CR-1 level is a useful diagnostic and prognostic marker for NSCLC patients.

摘要

引言

Cripto-1（CR-1）是表皮生长因子（EGF）-CFC蛋白家族的成员，参与肿瘤发病机制。

目的

本研究旨在探讨血清CR-1水平在非小细胞肺癌（NSCLC）患者中的诊断和预后价值。

方法

收集312例NSCLC患者和120例健康对照者的血清标本。采用酶联免疫吸附测定法检测血清CR-1水平。

结果

与健康对照相比，NSCLC患者血清CR-1水平显著升高（P <.001）。较高的血清CR-1水平与晚期TNM分期、淋巴结转移和远处转移相关。以1.67 ng/mL为临界值，CR-1对NSCLC具有良好的诊断性能。Kaplan-Meier对数秩分析显示，血清CR-1水平低的患者与血清CR-1水平高的患者相比，总生存期（OS）和无进展生存期（PFS）更好（分别为P =.004和.001）。进一步进行单因素和多因素Cox回归分析表明，血清CR-1水平是NSCLC患者预后的独立危险因素。